518 related articles for article (PubMed ID: 6210433)
21. Hodgkin's disease, mixed cellularity type, with a B-cell immunophenotype. Report of a case and literature review.
Siebert JD; McClure SP; Banks PM; Gulley ML
Arch Pathol Lab Med; 1995 May; 119(5):474-9. PubMed ID: 7538289
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical determination of CD23 expression in Hodgkin's disease using paraffin sections.
Rowlands DC; Hansel TT; Crocker J
J Pathol; 1990 Mar; 160(3):239-43. PubMed ID: 2139890
[TBL] [Abstract][Full Text] [Related]
23. Quantitative study of T and B lymphocytes in Hodgkin's disease.
Bensa JC; Micouin C; Schaerer R; Sotto JJ; Hollard D
Biomedicine; 1977 Apr; 26(2):137-44. PubMed ID: 326312
[TBL] [Abstract][Full Text] [Related]
24. Anti-Leu-3a antibody reactivity with Reed-Sternberg cells of Hodgkin's disease.
Oka K; Mori N; Kojima M
Arch Pathol Lab Med; 1988 Feb; 112(2):139-42. PubMed ID: 3257383
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease.
Doussis-Anagnostopoulou IA; Talks KL; Turley H; Debnam P; Tan DC; Mariatos G; Gorgoulis V; Kittas C; Gatter KC
J Pathol; 2002 Aug; 197(5):677-83. PubMed ID: 12210089
[TBL] [Abstract][Full Text] [Related]
26. The reaction of xenogeneic and monoclonal antisera with Reed-Sternberg cells.
Stuart AE; Jackson E; Morris CS
J Pathol; 1982 Jun; 137(2):129-38. PubMed ID: 6979620
[TBL] [Abstract][Full Text] [Related]
27. Relation of follicular dendritic reticulum cells to Reed-Sternberg cells of Hodgkin's disease with emphasis on the expression of CD21 antigen.
Delsol G; Meggetto F; Brousset P; Cohen-Knafo E; al Saati T; Rochaix P; Gorguet B; Rubin B; Voigt JJ; Chittal S
Am J Pathol; 1993 Jun; 142(6):1729-38. PubMed ID: 7685151
[TBL] [Abstract][Full Text] [Related]
28. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
[TBL] [Abstract][Full Text] [Related]
29. How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining.
Schmidt U; Herbst J; Metz KA; Leder LD
J Pathol; 1996 Jun; 179(2):138-44. PubMed ID: 8758204
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathways of adhesion in spontaneous rosetting of T-lymphocytes to the Hodgkin's cell line L428.
Sanders ME; Makgoba MW; Sussman EH; Luce GE; Cossman J; Shaw S
Cancer Res; 1988 Jan; 48(1):37-40. PubMed ID: 3275493
[TBL] [Abstract][Full Text] [Related]
31. Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses.
Fisher RI; Bates SE; Bostick-Bruton F; Tuteja N; Diehl V
J Immunol; 1984 May; 132(5):2672-7. PubMed ID: 6609204
[TBL] [Abstract][Full Text] [Related]
32. Immunological markers of peripheral blood and lymph node lymphocytes in Hodgkin's disease.
González M; Hernández F; San Miguel JF; Moraleda JM; Caballero MD; López Borrasca A
Neoplasma; 1985; 32(2):191-8. PubMed ID: 4000308
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin's disease with CD 20 (B1) positive Reed-Sternberg cells--an immunohistochemical and immunoelectron microscopic study.
Wachi E; Nakamura N; Abe M; Wakasa H
Fukushima J Med Sci; 1989 Dec; 35(2):69-77. PubMed ID: 2484830
[TBL] [Abstract][Full Text] [Related]
34. The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin's disease.
Lin P; Medeiros LJ; Wilder RB; Abruzzo LV; Manning JT; Jones D
Histopathology; 2004 Jun; 44(6):561-9. PubMed ID: 15186271
[TBL] [Abstract][Full Text] [Related]
35. Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease.
Facchetti F; De Wolf-Peeters C; van den Oord JJ; Desmet VJ
J Pathol; 1989 May; 158(1):57-65. PubMed ID: 2787853
[TBL] [Abstract][Full Text] [Related]
36. Lymphocyte profiles in patients with chronic low back pain enrolled in a clinical trial.
Brennan PC; Graham MA; Triano JJ; Hondras MA; Anderson RJ
J Manipulative Physiol Ther; 1994 May; 17(4):219-27. PubMed ID: 8046277
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
38. Differential diagnosis of L26-positive, CD15-negative Hodgkin's disease and large B-cell lymphoma with a high content of reactive T-cells: a morphologic and immunohistochemical study.
Nguyen DT; Diamond LW; Hansmann ML; Fischer R
Hematopathol Mol Hematol; 1996; 10(3):135-50. PubMed ID: 8878732
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of cellular markers in Epstein-Barr virus-positive Hodgkin's disease.
Bai MC; Jiwa NM; Horstman A; Vos W; Kluin PH; Van der Valk P; Mullink H; Walboomers JM; Meijer CJ
J Pathol; 1994 Sep; 174(1):49-55. PubMed ID: 7525910
[TBL] [Abstract][Full Text] [Related]
40. Quantitative ultrastructural analysis of in vivo lymphocyte-Reed-Sternberg cell interactions in Hodgkin's disease.
Archibald RB; Frenster JH
Natl Cancer Inst Monogr; 1973 May; 36():239-45. PubMed ID: 4542772
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
